Caris Life Sciences, Inc. is among the 12 Healthcare Stocks with Insider Buying in 2025, focusing on precision medicine with AI-driven insights for cancer detection and therapy selection. In Q2 2025, the company reported $181.4 million in revenue, an 81% increase YoY, with strong molecular profiling revenue growth and profitability. Recent findings in precision oncology and the validation of the MI Cancer Seek® assay highlight CAI’s commitment to refining diagnostic accuracy in oncology. The corporation’s AI-driven molecular insights in breast cancer subgroups demonstrate its dedication to delivering more precise, personalized cancer care. While CAI shows investment potential, there are other AI stocks with greater upside potential and lower downside risk.

Read more at Yahoo Finance: Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue